Review article: Medical therapy for fistulizing Crohn's disease

B. Bressler, B. E. Sands

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Background: Fistulae will develop in approximately one-third of patients with Crohn's disease. With an expected spontaneous healing rate of only 10%, fistulizing Crohn's disease requires a comprehensive strategy with a medical and possible surgical approach. Aim: To summarize the current literature evaluating various medical options for treating patients with fistulizing Crohn's disease. Methods: A literature review was conducted using PubMed (search terms: Crohn's disease and fistula) and manual search of references among the identified studies and relevant review papers to identify papers that present data on medical treatment of fistulizing Crohn's disease. Results: The first line of medical therapy remains antibiotics (metronidazole and ciprofloxacin). Mercaptopurine and azathioprine are medications that are effective in treating fistulizing Crohn's disease. The current gold standard of medical treatment to induce and maintain remission for fistulizing Crohn's disease is infliximab. Used as induction therapy, infliximab produced a 62% clinical response, and a complete closure rate of 46%. A maintenance therapy trial demonstrated at 54 weeks, 46% of patients receiving infliximab continued to respond to treatment, compared with 23% in the placebo group (P = 0.001). Conclusion: Further research to find new therapies and to improve our existing medical treatment of fistulizing Crohn's disease is required.

Original languageEnglish
Pages (from-to)1283-1293
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Issue number9
StatePublished - Nov 2006
Externally publishedYes


Dive into the research topics of 'Review article: Medical therapy for fistulizing Crohn's disease'. Together they form a unique fingerprint.

Cite this